Items Tagged ‘checkpoint inhibitors’

April 3, 2018

Breakthrough Therapy Designation Awarded for Enfortumab Vedotin in Locally Advanced or Metastatic Bladder Cancer

By

CancerConnect News: The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to enfortumab vedotin for patients with locally advanced or metastatic urothelial (bladder) cancer who were previously treated with checkpoint inhibitors. Breakthrough Therapy Designation is a process designed to expedite the development and review of drugs that are intended to treat a […]

View full entry

Tags: Bladder Cancer, checkpoint inhibitors, Enfortumab vedotin, News, PD-1, precision cancer medicines


February 26, 2018

Keytruda Improves Survival of Advanced Bladder Cancer

By

CancerConnect News: Patients with recurrent urothelial cancer lived longer when they received Keytruda (pembrolizumab) compared to chemotherapy as second-line treatment, according to long-term follow of a clinical trial presented at the Genitourinary Cancer Symposium.1 About Bladder Cancer Bladder cancer will be diagnosed in approximately 77,000 people in the United States this year alone. The average […]

View full entry

Tags: Bladder Cancer, checkpoint inhibitors, immunotherapy, keytruda, News, PD-1, pembrolizumab, Precision Cancer Medicine, treatment


January 8, 2018

First Line Combination Therapy Improves Progression-Free Survival In Advanced Lung Cancer

By

A recently reported study confirms that combination therapy using the “checkpoint inhibitor” Tecentriq® (atezolizumab) and chemotherapy as first line treatment for advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS), according to results of the phase III IMpower150 trial.1 About Lung Cancer Lung cancer remains the leading cause of cancer-related deaths worldwide. In the […]

View full entry

Tags: checkpoint inhibitors, immunotherapy, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, nivolumab, non-small cell lung cancer, opdivo, pembrolizumab, Precision Cancer Medicine, Tecentriq


September 25, 2017

FDA Adds Two Roche Multiple Myeloma Studies Evaluating Checkpoint Inhibitors to List of Partial Clinical Holds Over Safety Concerns

By

Alarmed that an imbalance in deaths among patients taking a combination of Keytruda (pembrolizumab) with Celgene’s Pomalyst and Revlimid could represent a threat in that whole class of checkpoint comboinations, the FDA has added two Tecentriq (atezolizumab) clinical studies to its growing list of clinical trials placed on partial hold over safety concerns while further […]

View full entry

Tags: checkpoint inhibitors, immunotherapy, Multiple Myeloma, News, PD-1, PD-L1